CD8A and ovarian cancer: Because class I HDAC inhibition has been reported to impair Treg programs22 and greater CD8‐Treg ratios are associated with improved outcomes in ovarian cancer patients,12 we next asked if ENT could alleviate Treg suppression in the ovarian cancer environment.